" class="no-js "lang="en-US"> Lundbeck Archives - Medtech Alert
Monday, November 11, 2024

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Otsuka and Lundbeck Announce FDA Approval of Supplemental New Drug Application for REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer’s Disease

Otsuka Pharmaceutical and Lundbeck announce the U.S. Food and Drug Administration (FDA) has approved the supplemental New […]

Neuro3 Therapeutics Acquires Exclusive Worldwide Rights to Develop and Commercialize Clinical Stage KCNQ2 Activators from Lundbeck

Neuro3 Therapeutics (Neuro3), a biotechnology company focused on the discovery and development of innovative medicines […]

Otsuka and Lundbeck Issue Statement on FDA Advisory Committee Meeting on REXULTI® for the Treatment of Agitation Associated with Alzheimer’s Dementia

Otsuka Pharmaceutical and Lundbeck Pharmaceuticals announce the Joint Meeting of the Psychopharmacologic Drugs Advisory Committee […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more